Magdalena Plebanski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/904148/publications.pdf

Version: 2024-02-01

211 papers

11,725 citations

²⁶⁵⁶⁷ 56
h-index

101 g-index

212 all docs 212 docs citations

times ranked

212

14883 citing authors

#	Article	IF	CITATIONS
1	Tranexamic acid alters the immunophenotype of phagocytes after lower limb surgery. Thrombosis Journal, 2022, 20, 17.	0.9	3
2	Low-Temperature Synthesis of Hollow \hat{I}^2 -Tricalcium Phosphate Particles for Bone Tissue Engineering Applications. ACS Biomaterials Science and Engineering, 2022, , .	2.6	2
3	Targeting Differential Roles of Tumor Necrosis Factor Receptors as a Therapeutic Strategy for Glaucoma. Frontiers in Immunology, 2022, 13, .	2.2	6
4	DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers, 2021, 13, 487.	1.7	16
5	Potential Impact of Human Cytomegalovirus Infection on Immunity to Ovarian Tumours and Cancer Progression. Biomedicines, 2021, 9, 351.	1.4	15
6	Anti-cancer effects of polyphenol-rich sugarcane extract. PLoS ONE, 2021, 16, e0247492.	1.1	21
7	Anti-Cancer Effects of Carnosine—A Dipeptide Molecule. Molecules, 2021, 26, 1644.	1.7	16
8	Morphology and Composition of Immunodiffusion Precipitin Complexes Evaluated via Microscopy and Proteomics. Journal of Proteome Research, 2021, 20, 2618-2627.	1.8	2
9	Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer. Diagnostics, 2021, 11, 1048.	1.3	5
10	Dinuclear orthometallated gold(I)-gold(III) anticancer complexes with potent <i>in vivo</i> activity through an ROS-dependent mechanism. Metallomics, 2021, 13, .	1.0	6
11	Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis. Frontiers in Oncology, 2021, 11, 692142.	1.3	123
12	Cancer Nanomedicine and Immune Systemâ€"Interactions and Challenges. Frontiers in Nanotechnology, 2021, 3, .	2.4	8
13	Adaptive Immunity and the Risk of Autoreactivity in COVID-19. International Journal of Molecular Sciences, 2021, 22, 8965.	1.8	35
14	Predicted B Cell Epitopes Highlight the Potential for COVID-19 to Drive Self-Reactive Immunity. Frontiers in Bioinformatics, 2021, 1 , .	1.0	10
15	Mapping Epitopes Recognised by Autoantibodies Shows Potential for the Diagnosis of High-Grade Serous Ovarian Cancer and Monitoring Response to Therapy for This Malignancy. Cancers, 2021, 13, 4201.	1.7	1
16	Chemoresistance is mediated by ovarian cancer leader cells in vitro. Journal of Experimental and Clinical Cancer Research, 2021, 40, 276.	3.5	5
17	Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. Proceedings of the National Academy of Sciences of the United States of America, $2021,118,.$	3.3	4
18	The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers. Biomedicines, 2021, 9, 1554.	1.4	2

#	Article	IF	CITATIONS
19	Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2021, 11, 1335.	1.1	13
20	Vitamin D supplementation increases adipokine concentrations in overweight or obese adults. European Journal of Nutrition, 2020, 59, 195-204.	1.8	19
21	Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment. Cells, 2020, 9, 33.	1.8	16
22	Influenzaâ€specific IgG1 ⁺ memory Bâ€cell numbers increase upon booster vaccination in healthy adults but not in patients with predominantly antibody deficiency. Clinical and Translational Immunology, 2020, 9, e1199.	1.7	12
23	Functional Recognition by CD8+ T Cells of Epitopes with Amino Acid Variations Outside Known MHC Anchor or T Cell Receptor Recognition Residues. International Journal of Molecular Sciences, 2020, 21, 4700.	1.8	2
24	Impact of ageâ€, cancerâ€, and treatmentâ€driven inflammation on T cell function and immunotherapy. Journal of Leukocyte Biology, 2020, 108, 953-965.	1.5	15
25	Pullulan-Coated Iron Oxide Nanoparticles for Blood-Stage Malaria Vaccine Delivery. Vaccines, 2020, 8, 651.	2.1	7
26	A profile of TNFR2+ regulatory T cells and CD103+ dendritic cells in the peripheral blood of patients with asthma. Human Immunology, 2020, 81, 634-643.	1.2	2
27	Limited Impact of Human Cytomegalovirus Infection in African Infants on Vaccine-Specific Responses Following Diphtheria-Tetanus-Pertussis and Measles Vaccination. Frontiers in Immunology, 2020, 11, 1083.	2.2	6
28	Sex-Differential Impact of Human Cytomegalovirus Infection on In Vitro Reactivity to Toll-Like Receptor 2, 4 and 7/8 Stimulation in Gambian Infants. Vaccines, 2020, 8, 407.	2.1	0
29	Dendritic Cells and Myeloid Derived Suppressor Cells Fully Responsive to Stimulation via Toll-Like Receptor 4 Are Rapidly Induced from Bone-Marrow Cells by Granulocyte-Macrophage Colony-Stimulating Factor. Vaccines, 2020, 8, 522.	2.1	8
30	A population of CD4 hi CD38 hi T cells correlates with disease severity in patients with acute malaria. Clinical and Translational Immunology, 2020, 9, e1209.	1.7	3
31	Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. Cells, 2020, 9, 2638.	1.8	138
32	Hypoxia Regulates DPP4 Expression, Proteolytic Inactivation, and Shedding from Ovarian Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 8110.	1.8	12
33	Antioxidant-Based Medicinal Properties of Stingless Bee Products: Recent Progress and Future Directions. Biomolecules, 2020, 10, 923.	1.8	69
34	Biodegradable PLGA-b-PEG Nanoparticles Induce T Helper 2 (Th2) Immune Responses and Sustained Antibody Titers via TLR9 Stimulation. Vaccines, 2020, 8, 261.	2.1	9
35	Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells. Cancers, 2020, 12, 673.	1.7	24
36	A Novel Approach for Non-Invasive Lung Imaging and Targeting Lung Immune Cells. International Journal of Molecular Sciences, 2020, 21, 1613.	1.8	12

#	Article	IF	CITATIONS
37	Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. Scientific Reports, 2020, 10, 2213.	1.6	37
38	Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines. Science Advances, 2020, 6, eaax2285.	4.7	85
39	Abstract 6338: High-throughput screening program to target ovarian cancer leader cells. , 2020, , .		0
40	Abstract 5547: Synergistic action of sitagliptin and checkpoint inhibition for ovarian cancer therapy. , 2020, , .		0
41	Abstract B69: Noninvasive tumor tracking and characterization of stage-specific immunity in a syngeneic mouse model of ovarian cancer., 2020,,.		0
42	Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis. Journal of Thrombosis and Haemostasis, 2019, 17, 2174-2187.	1.9	16
43	Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells. Cancers, 2019, 11, 1228.	1.7	39
44	Glycine microparticles loaded with functionalized nanoparticles for pulmonary delivery. International Journal of Pharmaceutics, 2019, 570, 118654.	2.6	15
45	Editorial: The Role of TNF-TNFR2 Signal in Immunosuppressive Cells and Its Therapeutic Implications. Frontiers in Immunology, 2019, 10, 2126.	2.2	6
46	A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy. Journal of Oncology, 2019, 2019, 1-13.	0.6	27
47	Gene expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells. Journal of Allergy and Clinical Immunology, 2019, 143, 2321-2325.	1.5	24
48	A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria. Frontiers in Immunology, 2019, 10, 331.	2.2	21
49	Tranexamic acid modulates the immune response and reduces postsurgical infection rates. Blood Advances, 2019, 3, 1598-1609.	2.5	68
50	Lipidomic profiling reveals early-stage metabolic dysfunction in overweight or obese humans. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 335-343.	1.2	30
51	Malaria vaccines in the eradication era: current status and future perspectives. Expert Review of Vaccines, 2019, 18, 133-151.	2.0	30
52	Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model. Cancers, 2019, 11, 32.	1.7	16
53	Effect of 16-weeks vitamin D replacement on calcium-phosphate homeostasis in overweight and obese adults. Journal of Steroid Biochemistry and Molecular Biology, 2019, 186, 169-175.	1.2	12
54	The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Seminars in Immunopathology, 2019, 41, 265-275.	2.8	160

#	Article	IF	CITATIONS
55	The emerging role of nanomaterials in immunological sensing — a brief review. Molecular Immunology, 2018, 98, 28-35.	1.0	10
56	Amino Acid Functionalized Inorganic Nanoparticles as Cutting-Edge Therapeutic and Diagnostic Agents. Bioconjugate Chemistry, 2018, 29, 657-671.	1.8	60
57	Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 183-192.	1.1	23
58	The Key Role of TNF-TNFR2 Interactions in the Modulation of Allergic Inflammation: A Review. Frontiers in Immunology, 2018, 9, 2572.	2.2	60
59	Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses. Frontiers in Immunology, 2018, 9, 2968.	2.2	23
60	Carnosine Supplementation Improves Serum Resistin Concentrations in Overweight or Obese Otherwise Healthy Adults: A Pilot Randomized Trial. Nutrients, 2018, 10, 1258.	1.7	19
61	Insights into endotoxin-mediated lung inflammation and future treatment strategies. Expert Review of Respiratory Medicine, 2018, 12, 941-955.	1.0	14
62	Development of Peptide Vaccines in Dengue. Current Pharmaceutical Design, 2018, 24, 1157-1173.	0.9	24
63	Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression. Cancers, 2018, 10, 276.	1.7	11
64	Therapeutic Cancer Vaccinesâ€"T Cell Responses and Epigenetic Modulation. Frontiers in Immunology, 2018, 9, 3109.	2.2	26
65	Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities. Current Medicinal Chemistry, 2018, 25, 4785-4806.	1.2	80
66	New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators. Current Medicinal Chemistry, 2018, 25, 4758-4784.	1.2	14
67	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC) Journal of Clinical Oncology, 2018, 36, 10097-10097.	0.8	1
68	Effect of a small natural dietary compound on lung pathology in airway inflammation. , 2018, , .		0
69	The Economics of Malaria Vaccine Development. Trends in Parasitology, 2017, 33, 154-156.	1.5	3
70	A flowcytometric analysis to efficiently quantify multiple innate immune cells and <scp>T</scp> Cell subsets in human blood. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 336-350.	1,1	22
71	Engineered Hydrogen-Bonded Glycopolymer Capsules and Their Interactions with Antigen Presenting Cells. ACS Applied Materials & Samp; Interfaces, 2017, 9, 6444-6452.	4.0	15
72	Understanding CD8 ⁺ Tâ€cell responses toward the native and alternate HLAâ€Aâ^—02:01â€restricte WT1 epitope. Clinical and Translational Immunology, 2017, 6, e134.	ed 1.7	24

#	Article	IF	Citations
73	Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annual Review of Cell and Developmental Biology, 2017, 33, 577-599.	4.0	355
74	Immunological effects among workers who handle engineered nanoparticles. Occupational and Environmental Medicine, 2017, 74, 868-876.	1.3	18
75	Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B activity in overweight/obese adults: a randomized placebo-controlled trial. Scientific Reports, 2017, 7, 15154.	1.6	33
76	Exacerbation of Ventilation-Induced Lung Injury and Inflammation in Preterm Lambs by High-Dose Nanoparticles. Scientific Reports, 2017, 7, 14704.	1.6	5
77	Sex-differential heterologous (non-specific) effects of vaccines: an emerging public health issue that needs to be understood and exploited. Expert Review of Vaccines, 2017, 16, 5-13.	2.0	24
78	Magnetic Nanovectors for the Development of DNA Blood-Stage Malaria Vaccines. Nanomaterials, 2017, 7, 30.	1.9	17
79	Vaccination with Altered Peptide Ligands of a Plasmodium berghei Circumsporozoite Protein CD8 T-Cell Epitope: A Model to Generate T Cells Resistant to Immune Interference by Polymorphic Epitopes. Frontiers in Immunology, 2017, 8, 115.	2.2	1
80	Negative Correlation between Circulating CD4+FOXP3+CD127â^' Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria–Tetanus–Pertussis Vaccine Implies a Regulatory Role. Frontiers in Immunology, 2017, 8, 921.	2.2	13
81	Minimal Sex-Differential Modulation of Reactivity to Pathogens and Toll-Like Receptor Ligands following Infant Bacillus Calmette–Guérin Russia Vaccination. Frontiers in Immunology, 2017, 8, 1092.	2.2	9
82	Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. Frontiers in Immunology, 2017, 8, 1482.	2.2	53
83	Synthetic Nanoparticles That Promote Tumor Necrosis Factor Receptor 2 Expressing Regulatory T Cells in the Lung and Resistance to Allergic Airways Inflammation. Frontiers in Immunology, 2017, 8, 1812.	2.2	13
84	Design of nanoparticle structures for cancer immunotherapy. , 2017, , 307-328.		1
85	Manipulating the microbiota to improve human health throughout life. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 379-381.	0.7	3
86	A Model to Study the Impact of Polymorphism Driven Liver-Stage Immune Evasion by Malaria Parasites, to Help Design Effective Cross-Reactive Vaccines. Frontiers in Microbiology, 2016, 7, 303.	1.5	13
87	Changing oral vaccine to inactivated polio vaccine might increase mortality. Lancet, The, 2016, 387, 1054-1055.	6.3	21
88	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	6.6	645
89	Sex-Differential Non-Vaccine-Specific Immunological Effects of Diphtheria-Tetanus-Pertussis and Measles Vaccination. Clinical Infectious Diseases, 2016, 63, ciw492.	2.9	31
90	The global challenge and future strategies for keeping the world's aging population healthy by vaccination. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 427-431.	0.7	4

#	Article	IF	Citations
91	Alteration of early dendritic cell activation by cancer cell lines predisposes immunosuppression, which cannot be reversed by TLR4 stimulation. Acta Biochimica Et Biophysica Sinica, 2016, 48, 1101-1111.	0.9	2
92	Low dose cyclophosphamide: Mechanisms of T cell modulation. Cancer Treatment Reviews, 2016, 42, 3-9.	3.4	117
93	Nanoparticles, Immunomodulation and Vaccine Delivery. Frontiers in Nanobiomedical Research, 2016, , 101-127.	0.1	O
94	Polymorphism in liver-stage malaria vaccine candidate proteins: immune evasion and implications for vaccine design. Expert Review of Vaccines, 2016, 15, 389-399.	2.0	15
95	Abstract IA17: Gut microbiota controls immuneresponses during cancer therapy. , 2016, , .		0
96	Two-dimensional single-cell patterning with one cell per well driven by surface acoustic waves. Nature Communications, 2015, 6, 8686.	5.8	430
97	The Use of Synthetic Carriers in Malaria Vaccine Design. Vaccines, 2015, 3, 894-929.	2.1	22
98	A Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes. Vaccines, 2015, 3, 875-893.	2.1	9
99	Editorial: Why Vaccines to HIV, HCV, and Malaria Have So Far Failed—Challenges to Developing Vaccines Against Immunoregulating Pathogens. Frontiers in Microbiology, 2015, 6, 1318.	1.5	12
100	Dendritic Cell-Mediated Phagocytosis but Not Immune Activation Is Enhanced by Plasmin. PLoS ONE, 2015, 10, e0131216.	1.1	44
101	Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. BioMed Research International, 2015, 2015, 1-21.	0.9	227
102	Maintenance lenalidomide in combination with 5â€azacitidine as postâ€remission therapy for acute myeloid leukaemia. British Journal of Haematology, 2015, 169, 199-210.	1.2	29
103	Montanide, Poly I:C and nanoparticle based vaccines promote differential suppressor and effector cell expansion: a study of induction of CD8 T cells to a minimal Plasmodium berghei epitope. Frontiers in Microbiology, 2015, 6, 29.	1.5	33
104	Heterologous and sex differential effects of administering vitamin A supplementation with vaccines. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 36-45.	0.7	12
105	Nanoparticles modify dendritic cell homeostasis and induce non-specific effects on immunity to malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 70-76.	0.7	11
106	Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine. Vaccine, 2015, 33, 5950-5959.	1.7	9
107	Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients. Clinical Cancer Research, 2014, 20, 724-735.	3.2	76
108	Plasmodium falciparum induces Foxp3hi CD4 T cells independent of surface PfEMP1 expression via small soluble parasite components. Frontiers in Microbiology, 2014, 5, 200.	1.5	16

#	Article	IF	CITATIONS
109	Lenalidomideâ€based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. American Journal of Hematology, 2014, 89, 795-802.	2.0	63
110	The effects of engineered nanoparticles on pulmonary immune homeostasis. Drug Metabolism Reviews, 2014, 46, 176-190.	1.5	41
111	Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. Journal of Translational Medicine, 2014, 12, 179.	1.8	14
112	Design of magnetic polyplexes taken up efficiently by dendritic cell for enhanced DNA vaccine delivery. Gene Therapy, 2014, 21, 212-218.	2.3	40
113	Antibodies to a Single, Conserved Epitope in Anopheles APN1 Inhibit Universal Transmission of Plasmodium falciparum and Plasmodium vivax Malaria. Infection and Immunity, 2014, 82, 818-829.	1.0	62
114	Characterisation of local immune responses induced by a novel nano-particle based carrier-adjuvant in sheep. Veterinary Immunology and Immunopathology, 2013, 155, 21-29.	0.5	13
115	Differential Uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets Induces Discrete Immunological Imprints. Journal of Immunology, 2013, 191, 5278-5290.	0.4	83
116	The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development. Diabetologia, 2013, 56, 2659-2668.	2.9	7
117	IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nature Communications, 2013, 4, 2333.	5.8	193
118	Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods, 2013, 60, 232-241.	1.9	42
119	Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clinical Immunology, 2013, 149, 97-110.	1.4	108
120	On the efficacy of malaria DNA vaccination with magnetic gene vectors. Journal of Controlled Release, 2013, 168, 10-17.	4.8	18
121	Nanoparticles, Immunomodulation and Vaccine Delivery. Frontiers in Nanobiomedical Research, 2013, , 449-475.	0.1	7
122	EDITORIAL: Nanotechnology and vaccine development: Methods to study and manipulate the interaction of nanoparticles with the immune system. Methods, 2013, 60, 225.	1.9	7
123	The signalling imprints of nanoparticle uptake by bone marrow derived dendritic cells. Methods, 2013, 60, 275-283.	1.9	20
124	Phenotypic analysis of ovine antigen presenting cells loaded with nanoparticles migrating from the site of vaccination. Methods, 2013 , 60 , $257-263$.	1.9	5
125	The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax, 2013, 68, 9-18.	2.7	43
126	TNFR2 Expression on CD25hiFOXP3+ T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors. Frontiers in Immunology, 2013, 4, 233.	2.2	25

#	Article	IF	CITATIONS
127	Myeloid Derived Suppressor Cells and Their Role in Diseases. Current Medicinal Chemistry, 2013, 20, 1437-1444.	1.2	65
128	Inert 50-nm Polystyrene Nanoparticles That Modify Pulmonary Dendritic Cell Function and Inhibit Allergic Airway Inflammation. Journal of Immunology, 2012, 188, 1431-1441.	0.4	51
129	Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy. Cancers, 2012, 4, 581-600.	1.7	12
130	Induction of Multi-Functional T Cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals. PLoS ONE, 2012, 7, e39368.	1.1	8
131	The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes. Malaria Journal, 2011, 10, 266.	0.8	12
132	CD38 identifies a hypoâ€proliferative ILâ€13â€secreting CD4 ⁺ Tâ€cell subset that does not fit into existing naive and memory phenotype paradigms. European Journal of Immunology, 2011, 41, 1298-1308.	1.6	21
133	N,N′-Carbonyldiimidazole-mediated functionalization of superparamagnetic nanoparticles as vaccine carrier. Colloids and Surfaces B: Biointerfaces, 2011, 83, 83-90.	2.5	31
134	Differential Cellular Recognition of Antigens During Acute Plasmodium falciparum and Plasmodium vivax Malaria. Journal of Infectious Diseases, 2011, 203, 1192-1199.	1.9	7
135	Heroes or villains? T regulatory cells in malaria infection. Trends in Parasitology, 2010, 26, 16-25.	1.5	65
136	Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2010, 2, 205-218.	3.3	67
137	Growth-Inhibitory Antibodies Are Not Necessary for Protective Immunity to Malaria Infection. Infection and Immunity, 2010, 78, 680-687.	1.0	14
138	The challenge of assessing infant vaccine responses in resource-poor settings. Expert Review of Vaccines, 2010, 9, 665-674.	2.0	18
139	A Complementary Role for the Tetraspanins CD37 and Tssc6 in Cellular Immunity. Journal of Immunology, 2010, 185, 3158-3166.	0.4	44
140	Interleukin-13 Regulates Secretion of the Tumor Growth Factor–β Superfamily Cytokine Activin A in Allergic Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 667-675.	1.4	27
141	Methods to measure T-cell responses. Expert Review of Vaccines, 2010, 9, 595-600.	2.0	16
142	Plasmodium falciparum–Mediated Induction of Human CD25hiFoxp3hi CD4 T Cells Is Independent of Direct TCR Stimulation and Requires IL-2, IL-10 and TGFβ. PLoS Pathogens, 2009, 5, e1000543.	2.1	121
143	Analysis of FOXP3+ Regulatory T Cells That Display Apparent Viral Antigen Specificity during Chronic Hepatitis C Virus Infection. PLoS Pathogens, 2009, 5, e1000707.	2.1	31
144	Parasite-Dependent Expansion of TNF Receptor Il–Positive Regulatory T Cells with Enhanced Suppressive Activity in Adults with Severe Malaria. PLoS Pathogens, 2009, 5, e1000402.	2.1	118

#	Article	IF	Citations
145	Hot, sweet and sticky: the glycobiology of Plasmodium falciparum. Trends in Parasitology, 2008, 24, 210-218.	1.5	63
146	Malaria vaccines: into a mirror, darkly?. Trends in Parasitology, 2008, 24, 532-536.	1.5	8
147	Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films. Malaria Journal, 2008, 7, 62.	0.8	21
148	The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert Opinion on Biological Therapy, 2008, 8, 1873-1884.	1.4	37
149	Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads. Vaccine, 2008, 26, 2706-2713.	1.7	43
150	Promising particle-based vaccines in cancer therapy. Expert Review of Vaccines, 2008, 7, 1103-1119.	2.0	61
151	Antibodies to <i>Plasmodium falciparum</i> i>and <i>Plasmodium vivax</i> Merozoite Surface Protein 5 in Indonesia: Speciesâ€Specific and Crossâ€Reactive Responses. Journal of Infectious Diseases, 2008, 198, 134-142.	1.9	65
152	Natural Regulatory T Cells and Persistent Viral Infection. Journal of Virology, 2008, 82, 21-30.	1.5	139
153	Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in Kenyans. PLoS ONE, 2008, 3, e2027.	1.1	82
154	Poly-l-lysine-coated nanoparticles: A potent delivery system to enhance DNA vaccine efficacy. Vaccine, 2007, 25, 1316-1327.	1.7	122
155	Defining target antigens for CD25 + FOXP3 + IFNâ€₁³ â^² regulatory T cells in chronic hepatitis C virus infection. Immunology and Cell Biology, 2007, 85, 197-204.	1.0	50
156	Mannan-mediated gene delivery for cancer immunotherapy. Immunology, 2007, 120, 325-335.	2.0	52
157	Predicting memory: a prospective readout for malaria vaccines?. Trends in Parasitology, 2007, 23, 341-343.	1.5	6
158	Type 1 and 2 Immunity Following Vaccination Is Influenced by Nanoparticle Size:Â Formulation of a Model Vaccine for Respiratory Syncytial Virus. Molecular Pharmaceutics, 2007, 4, 73-84.	2.3	258
159	Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Research, 2006, 8, R27.	2.2	150
160	Pathogen recognition and development of particulate vaccines: Does size matter?. Methods, 2006, 40, 1-9.	1.9	509
161	Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods, 2006, 40, 20-29.	1.9	81
162	Economic and practical challenges to the formulation of vaccines against endemic infectious diseases such as malaria. Methods, 2006, 40, 77-85.	1.9	7

#	Article	IF	Citations
163	Systemic immune responses in sheep, induced by a novel nano-bead adjuvant. Vaccine, 2006, 24, 1124-1131.	1.7	64
164	Alveolar macrophage function is altered in patients with lung cancer. Clinical and Experimental Immunology, 2006, 143, 363-372.	1.1	38
165	DimorphicPlasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. European Journal of Immunology, 2006, 36, 1168-1178.	1.6	23
166	Regulatory T-Cells: Immunomodulators in Health and Disease. Current Topics in Medicinal Chemistry, 2006, 6, 1759-1768.	1.0	7
167	CELLULAR REACTIVITY TO THE P. FALCIPARUM PROTEIN TRAP IN ADULT KENYANS: NOVEL EPITOPES, COMPLEX CYTOKINE PATTERNS, AND THE IMPACT OF NATURAL ANTIGENIC VARIATION. American Journal of Tropical Medicine and Hygiene, 2006, 74, 367-375.	0.6	22
168	Direct processing and presentation of antigen from malaria sporozoites by professional antigenâ€presenting cells in the induction of CD8 + Tâ€cell responses. Immunology and Cell Biology, 2005, 83, 307-312.	1.0	49
169	Selectively Impaired CD8+ but Not CD4+ T Cell Cycle Arrest during Priming as a Consequence of Dendritic Cell Interaction with Plasmodium-Infected Red Cells. Journal of Immunology, 2005, 175, 3525-3533.	0.4	31
170	Dendritic Cells Induce Immunity and Long-Lasting Protection against Blood-Stage Malaria despite an In Vitro Parasite-Induced Maturation Defect. Infection and Immunity, 2004, 72, 5331-5339.	1.0	52
171	A Regulatory Role for CD37 in T Cell Proliferation. Journal of Immunology, 2004, 172, 2953-2961.	0.4	128
172	Vaccines that facilitate antigen entry into dendritic cells. Immunology and Cell Biology, 2004, 82, 506-516.	1.0	181
173	A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nature Medicine, 2004, 10, 406-410.	15.2	242
174	Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clinical and Experimental Immunology, 2004, 135, 286-293.	1.1	69
175	A new boost for malaria vaccines. Trends in Parasitology, 2004, 20, 157-160.	1.5	3
176	Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors. Journal of Immunology, 2004, 173, 3148-3154.	0.4	603
177	Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine, 2004, 23, 258-266.	1.7	73
178	Delivery of a heterologous antigen by a registeredSalmonellavaccine (STM1). FEMS Microbiology Letters, 2003, 227, 211-217.	0.7	30
179	Aspects of cancer immunotherapy. Immunology and Cell Biology, 2003, 81, 79-85.	1.0	9
180	A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15029-15034.	3.3	82

#	Article	IF	CITATIONS
181	EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-430.	0.6	34
182	Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-30.	0.6	23
183	Induction of T Helper Type 1 and 2 Responses to 19-Kilodalton Merozoite Surface Protein 1 in Vaccinated Healthy Volunteers and Adults Naturally Exposed to Malaria. Infection and Immunity, 2002, 70, 1417-1421.	1.0	35
184	Applications of Peptide Mimetics in Cancer. Current Medicinal Chemistry, 2002, 9, 411-420.	1.2	12
185	Naturally Exposed Populations Differ in Their T1 and T2 Responses to the Circumsporozoite Protein of Plasmodium falciparum. Infection and Immunity, 2002, 70, 1468-1474.	1.0	14
186	Crystal Structure of a Non-canonical Low-affinity Peptide Complexed with MHC Class I: A New Approach For Vaccine Design. Journal of Molecular Biology, 2002, 318, 1293-1305.	2.0	65
187	Crystal Structure of a Non-canonical High Affinity Peptide Complexed with MHC Class I: A Novel Use of Alternative Anchors. Journal of Molecular Biology, 2002, 318, 1307-1316.	2.0	29
188	Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime–boost immunisation regimes. Vaccine, 2002, 20, 1039-1045.	1.7	156
189	Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. Journal of Clinical Investigation, 2002, 110, 295-301.	3.9	10
190	Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. Journal of Clinical Investigation, 2002, 110, 295-301.	3.9	10
191	Unique T Cell Effector Functions Elicited byPlasmodium falciparumEpitopes in Malaria-Exposed Africans Tested by Three T Cell Assays. Journal of Immunology, 2001, 167, 4729-4737.	0.4	57
192	The immunology of malaria infection. Current Opinion in Immunology, 2000, 12, 437-441.	2.4	113
193	Inducible Expression of the Cell Surface Heparan Sulfate Proteoglycan Syndecan-2 (Fibroglycan) on Human Activated Macrophages Can Regulate Fibroblast Growth Factor Action. Journal of Biological Chemistry, 1999, 274, 24113-24123.	1.6	110
194	Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature, 1999, 400, 73-77.	13.7	553
195	Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunological Reviews, 1999, 170, 29-38.	2.8	179
196	Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nature Medicine, 1999, 5, 565-571.	15.2	96
197	Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein ofPlasmodium falciparum in West Africans. European Journal of Immunology, 1999, 29, 1943-1954.	1.6	47
198	Potent Induction of Focused Th1â€Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a RecombinantPlasmodium falciparumMalaria Vaccine. Journal of Infectious Diseases, 1999, 180, 1656-1664.	1.9	148

#	ARTICLE	IF	CITATIONS
199	Interleukin 10–Mediated Immunosuppression by a Variant CD4 T Cell Epitope of Plasmodium falciparum. Immunity, 1999, 10, 651-660.	6.6	114
200	Protection fromPlasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. European Journal of Immunology, 1998, 28, 4345-4355.	1.6	80
201	Association of Malaria Parasite Population Structure, HLA, and Immunological Antagonism. Science, 1998, 279, 1173-1177.	6.0	278
202	Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. , 1998, 28, 4345.		6
203	Genetic analysis of host–parasite coevolution in human malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1317-1325.	1.8	70
204	A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnology, 1997, 15, 1280-1284.	9.4	153
205	Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. European Journal of Immunology, 1996, 26, 1951-1959.	1.6	89
206	Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. European Journal of Immunology, 1995, 25, 1783-1787.	1.6	44
207	Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet, The, 1995, 345, 1003-1007.	6.3	154
208	In vitro primary responses of human T cells to soluble protein antigens. Journal of Immunological Methods, 1994, 170, 15-25.	0.6	39
209	Dependency on interleukin-1 of primary humanin vitro T cell responses to soluble antigens. European Journal of Immunology, 1992, 22, 2353-2358.	1.6	21
210	Synthesis of the surface glycoprotein of rotavirus SA11 in the aroA strain of Salmonella typhimurium SL3261. Research in Microbiology, 1990, 141, 883-886.	1.0	22
211	Robust and Prototypical Immune Responses Towards Influenza Vaccines in the High-Risk Group of Indigenous Australians. SSRN Electronic Journal, 0, , .	0.4	0